Elevance Health Inc.
NYSE:ELVMedical - Healthcare Plans
-$3.45 today
- Market cap
- $86.60B
- Beta
- 0.68
- P/E (TTM)
- 16.3
- EPS (TTM)
- $23.78
- Dividend yield
- 1.77%
Volume 1.91M
Average 1.68M
ELV Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Elevance Health Inc.NYSE: ELV
Net Receivables · Q3 FY2026 · quarter ended Sep 2026
Net receivables rises 67.7% from a year ago
Net receivables stood at $24.57B at the end of Q3 FY2026, up 67.7% from a year earlier and up 5.0% from the prior quarter. Over 3 fiscal years it compounded at +9.1% a year.
Context
- Net receivables amounted to 19.2% of total assets at the end of Q3 FY2026, up 7.3 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +67.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 15.24B USD
- Year-over-year change
- +16.7%
- 4-year CAGR
- +12.0%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.24B | +16.7% |
| FY2024 | 2024-12-31 | 13.06B | +4.8% |
| FY2023 | 2023-12-31 | 12.46B | +6.1% |
| FY2022 | 2022-12-31 | 11.75B | +21.2% |
| FY2021 | 2021-12-31 | 9.69B | — |
Net Receivables vs competitors
How ELV compares with its peers on the latest reported figures
- ELV's Sep 2026 net receivables of $24.57B is the 3rd highest of the 9 companies compared; the peer median is $10.72B.
- Its year-over-year change of +67.7% is the highest of 9, against a peer median of -2.6%.
- Net receivables amounts to 19.2% of total assets for ELV, versus a peer median of 17.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $40.31B | -0.8% | +13.4% | 15.9% | |
| Sep 2026 | $31.49B | -0.7% | +19.2% | 20.0% | |
| Sep 2026 | $24.57B | +67.7% | +9.1% | 19.2% | |
| Sep 2026 | $20.54B | -62.9% | +20.1% | 6.6% | |
| Jun 2026 | $18.08B | -16.1% | +10.9% | 21.8% | |
| Sep 2026 | $3.36B | -4.4% | +15.3% | 21.5% | |
| Sep 2026 | $2.87B | +6.7% | +25.0% | 5.0% | |
| Jun 2026 | $380.06M | -49.0% | -27.5% | 3.4% | |
| Mar 2026 | $277.68M | +29.7% | +39.7% | 22.0% | |
| Peer median (excluding ELV) | $10.72B | -2.6% | +17.3% | 17.9% | |
Competitors are the stored peer set for ELV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.88B | 7.39B | 6.53B | 8.29B | 9.49B |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 9.69B | 11.75B | 12.46B | 13.06B | 15.24B |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 14.57B | 19.13B | 18.99B | 21.34B | 24.73B |
| Property, Plant & Equipment (Net) | 4.55B | 4.92B | 4.94B | 5.22B | 5.13B |
| Goodwill | 24.23B | 24.38B | 25.32B | 28.28B | 28.34B |
| Intangible Assets | 10.62B | 10.32B | 10.27B | 12.09B | 11.2B |
| Long-term Investments | 34.01B | 33.34B | 36.83B | 37.18B | 38.58B |
| Tax Assets | 103M | 137M | 228M | 206M | 298M |
| Other Non-current Assets | 9.39B | 10.53B | 12.36B | 12.57B | 13.21B |
| Total Non-current Assets | 82.89B | 83.62B | 89.94B | 95.55B | 96.77B |
| Total Assets | 97.46B | 102.76B | 108.93B | 116.89B | 121.49B |
| Account Payables | 13.52B | 15.6B | 16.11B | 15.75B | 17.08B |
| Short-term Debt | 2.01B | 1.95B | 2.04B | 2.17B | 1.38B |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 1.11B | 1.4B | 1.51B | 1.49B |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 15.53B | 18.65B | 19.55B | 19.42B | 19.96B |
| Long-term Debt | 22.02B | 23.1B | 23.93B | 29.88B | 31.33B |
| Deferred Tax Liabilities | 2.81B | 2.02B | 1.97B | 2.15B | 2.11B |
| Deferred Revenue (Non-current) | 1.15B | 1.11B | 0 | 0 | 0 |
| Other Non-current Liabilities | 18.96B | 20.79B | 23.39B | 23.36B | 23.55B |
| Total Non-current Liabilities | 45.81B | 47.77B | 49.97B | 56.04B | 57.51B |
| Total Liabilities | 61.33B | 66.43B | 69.52B | 75.46B | 77.47B |
| Common Stock | 2M | 2M | 2M | 2M | 2M |
| Retained Earnings | 27.09B | 29.65B | 31.75B | 33.55B | 35.39B |
| Accumulated OCI | (178M) | (2.49B) | (1.31B) | (1.15B) | (451M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 68M | 87M | 99M | 111M | 144M |
| Total Equity | 36.13B | 36.33B | 39.41B | 41.43B | 44.03B |
| Total Debt | 24.89B | 25.8B | 26.65B | 32.7B | 33.24B |
| Net Debt | 20.01B | 18.41B | 20.13B | 24.41B | 23.74B |
Elevance Health Inc.
NYSE:ELV
Intrinsic Alpha fair value
Locked
Current Price
$400.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.